Thanks for your visit.
Our website is getting a makeover. We hope you'll come back and see us soon.
At Bayer, oncology is more than just a therapeutic interest. Our singular vision is to improve the lives of individuals touched by cancer.
As a global organization with widespread reach and impact, we are applying our experience, knowledge, and passion to make life better for patients who are faced with challenging diseases across the globe.
While much progress has been made in the treatment of cancer, there is still a need for improved diagnosis and treatment. Our ultimate goal is to be able to treat cancer as a chronic disease. Our research and product development focus on identifying innovative therapies that target key pathomechanisms. In addition to our clinical development program, we work hard to further enhance products that have already been approved. This product-accompanying development, also known as life-cycle management, aims to exploit a drug's full potential, for example, by extending its range of application to other indications or improving its tolerability for patients. To ensure the clinical development and approval of our pipeline assets, as well as life cycle management programs of our marketed products, we employ integrated medical affairs and regulatory affairs support to all of our commercial activities.
Another important aspect of our strategy is cooperation with external partners in science and industry, such as universities, advocacy groups, cooperative groups, and pharmaceutical companies, who have specialized knowledge and are willing to join us in taking on the challenges of developing and marketing new products. We are dedicated to fulfilling our purpose of discovering innovative cancer-fighting therapies and providing personalized solutions as quickly as possible to patients and physicians. In the end, our passion, innovation, and dedication bring to market products that carry hope, well-being, and life to people with cancer.
Learn more about Nexavar at Bayer HealthCare
